Print Page   |   Sign In   |   Register
Companies: Soligenix, Inc. (SNGX)

Company Profile

Description

We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: BioTherapeutics and Vaccines/BioDefense. Our BioTherapeutics business segment is developing a first-in-class photo-dynamic therapy (SGX301) utilizing safe, visible light for the treatment of cutaneous T-cell lymphoma ("CTCL"), proprietary formulations of oral beclomethasone 17,21-dipropionate ("BDP") for the prevention/treatment of gastrointestinal ("GI") disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and our novel innate defense regulator ("IDR") technology (SGX942) for the treatment of oral mucositis in head and neck cancer. Our Vaccines/BioDefense business segment includes active development programs for RiVax, our ricin toxin vaccine candidate, VeloThrax, our anthrax vaccine candidate, OrbeShield, our GI acute radiation syndrome ("GI ARS") therapeutic candidate and SGX943, our melioidosis therapeutic candidate. The development of our vaccine programs is supported by our heat stabilization technology, known as ThermoVax, under existing and on-going government contract funding. With the recently awarded government contract from the National Institute of Allergy and Infectious Diseases ("NIAID"), we will attempt to advance the development of RiVax to protect against exposure to ricin toxin. We plan to use the funds received under our government contracts with the Biomedical Advanced Research and Development Authority ("BARDA") and NIAID to advance the development of OrbeShield for the treatment of GI ARS.

 
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201). Our Vaccines/BioDefense business segment includes active development programs for RiVax, our ricin toxin vaccine candidate, OrbeShield, our GI acute radiation syndrome therapeutic candidate and SGX943, our melioidosis therapeutic candidate. The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax. Currently, this business segment is supported with up to $58 million in government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
  

 

Contact Information

  • 29 Emmons Drive
  • Suite C-10
  • Princeton, NJ 08540



Financial Reporting/Disclosure

Reporting Status U.S. Reporting: SEC Reporting
Latest Report Jun 30, 2017 10-Q
CIK 0000812796
Fiscal Year End 12/31
OTC Marketplace Not Available

Profile Data

SIC - Industry Classification Not Available
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available

Service Providers

Accounting/Auditing Firm
EisnerAmper LLP
101 West Avenue
P.O. Box 458
Jenkintown,PA,19046
United States
Securities Counsel
Duane Morris LLP
1540 Broadway
New York,NY,10036-4086
United States
Investor Relations Firm

Not Available

Company History

  • Formerly=DOR BioPharma, Inc. until 9-2009
  • Formerly=Endorex Corp. until 12-01
  • Formerly=ImmunoTherapeutics, Inc. until 9-96

 
Community Search
Sign In